Merus N.V. (NASDAQ:MRUS) – Stock analysts at Wedbush lifted their Q2 2017 EPS estimates for shares of Merus N.V. in a research note issued to investors on Wednesday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings of ($0.72) per share for the quarter, up from their previous forecast of ($0.78). Wedbush has a “Outperform” rating and a $32.00 price objective on the stock. Wedbush also issued estimates for Merus N.V.’s Q3 2017 earnings at ($0.78) EPS, Q4 2017 earnings at ($0.93) EPS, FY2018 earnings at ($4.74) EPS, FY2019 earnings at ($5.29) EPS, FY2020 earnings at ($5.23) EPS and FY2021 earnings at ($3.23) EPS.

Other research analysts also recently issued reports about the stock. ValuEngine raised shares of Merus N.V. from a “sell” rating to a “hold” rating in a research report on Saturday, May 20th. Zacks Investment Research downgraded shares of Merus N.V. from a “hold” rating to a “sell” rating in a research report on Friday, May 5th. Citigroup Inc. cut shares of Merus N.V. from a “buy” rating to a “neutral” rating and set a $31.00 price target on the stock. in a research note on Tuesday, March 21st. Finally, Jefferies Group LLC restated a “buy” rating and set a $33.00 price target on shares of Merus N.V. in a research note on Wednesday, April 26th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. Merus N.V. currently has an average rating of “Hold” and a consensus price target of $26.00.

TRADEMARK VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/08/merus-n-v-mrus-to-post-q2-2017-earnings-of-0-72-per-share-wedbush-forecasts-updated-updated-updated.html.

Shares of Merus N.V. (MRUS) opened at 16.85 on Friday. Merus N.V. has a 12 month low of $8.00 and a 12 month high of $33.63. The firm’s market capitalization is $312.40 million. The firm’s 50-day moving average is $17.76 and its 200 day moving average is $21.82.

Hedge funds have recently bought and sold shares of the company. Spark Investment Management LLC purchased a new stake in Merus N.V. during the first quarter valued at about $458,000. Renaissance Technologies LLC bought a new stake in Merus N.V. during the first quarter valued at $549,000. Norges Bank bought a new stake in Merus N.V. during the fourth quarter valued at $790,000. Victory Capital Management Inc. bought a new stake in Merus N.V. during the first quarter valued at $976,000. Finally, Iguana Healthcare Management LLC boosted its stake in Merus N.V. by 16.7% in the first quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after buying an additional 25,000 shares during the period. Institutional investors and hedge funds own 32.59% of the company’s stock.

Merus N.V. Company Profile

Earnings History and Estimates for Merus N.V. (NASDAQ:MRUS)

Receive News & Stock Ratings for Merus N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus N.V. and related stocks with our FREE daily email newsletter.